KROS biotech catalysts & pipeline

KEROS THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

H2 2026

We also plan to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026.

H1 2027

• Initial data expected in the first half of 2027